1 / 36

The Clinical significance of DNA ploidy as a prognostic factor in patients with Borderline Ovarian Tumor Retrospective

The Clinical significance of DNA ploidy as a prognostic factor in patients with Borderline Ovarian Tumor Retrospective study. Ji Young Lee, MD, PhD, David Marchetti, MD, M Steven Piver, MD Department of Obstetrics and Gynecology Sisters of Charity Hospital, Buffalo, NY. INTRODUCTION.

tate
Download Presentation

The Clinical significance of DNA ploidy as a prognostic factor in patients with Borderline Ovarian Tumor Retrospective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Clinical significance of DNA ploidyas a prognostic factor in patients with Borderline Ovarian TumorRetrospective study Ji Young Lee, MD, PhD, David Marchetti, MD, M Steven Piver, MD Department of Obstetrics and Gynecology Sisters of Charity Hospital, Buffalo, NY

  2. INTRODUCTION

  3. Howard Taylor Described Borderline Ovarian Tumor as “semi-malignant” ….propensity to metastasize but maintained a rather indolent course… Surg Gynecol Obstet 1929; 48: 204-230

  4. 10-20% of epithelial ovarian tumor Mean age 45.7 yr 75% of tumors are Stage I 5 YSR for early stage tumors ≥ 95% Recurrence rate 8~32% Risk factors for recurrence FIGO stage, Age, Residual disease, Histology, DNA ploidy etc.

  5. DNA Ploidy The most important prognostic factor in 370 patients with the borderline ovarian tumor Int J Gynecol Oncol 1993 3: 349

  6. A Review of the Literature

  7. OBJECTIVES Report the results regarding DNA ploidy and other Clinicopathologic variables 2. Evaluate the clinical significance of DNA Ploidy in 30 consecutive patients with Borderline Ovarian Tumor

  8. MATERIALS & METHODS

  9. Retrospective Study Review of Cancer Registry of Sisters Hospital A total of 30 consecutive patients with Borderline Ovarian Tumor Histologic evaluation of Paraffin Tissue Blocks DNA Flow Cytometry for DNA ploidy Analysis -Primary Tumor

  10. Histology Definition Malignant characteristics of epithelial hyperplasia or stratification, mitotic activity, and cellular/nuclear atypia No Stromal Invasion MUCINOUS TYPE

  11. DNA Flow Cytometryby USLABS (Irvine, CA) Diploid ( DI=1.0, single peak) Aneuploid (DI;1.1-1.9), Multi-peak

  12. RESULTS ….and DISCUSSION

  13. Age Distribution of Borderline Ovarian Tumor MEAN AGE 54.5 yo Patients (No.) Age

  14. Age distribution of Borderline Ovarian TumorSep 1993 – Sep 2004 in Sweden Int J Gynecol Cancer 2008;18:453–459.

  15. Histology and Age Distribution of Borderline Ovarian Tumor Patients (No.) Serous Mucinous Mixed Age

  16. DNA Ploidy and Age at Diagnosis Diploid Patients (No.) Aneuploid Age

  17. The relationship of Histopathologyand FIGO stage of disease

  18. The relationship of DNA ploidy and Histology of disease

  19. DNA ploidy and Histologic type Patients (No.) Histology-DNA Ploidy

  20. The relationship of DNA ploidy and FIGO stage of disease

  21. DNA Ploidy and Disease Stage Diploid Patients (No.) Aneuploid Stage-DNA Ploidy

  22. Characteristics of 30 patients

  23. HistologyBorderline Ovarian Tumor Tropé CG. Seminars in surgical oncology 2000 9(1)69 –75

  24. The relation of histopathology to ploidy status Histopathology Number Diploid Aneuploid No FCM of cases (%) Serous 219 (54.9) 167 27 25 Mucinous 171 (42.9) 127 32 12 Endometrioid 5 (1.2) 3 2 — Clear cell 1 (0.2) — 1 — Mixed 3 (0.8) 2 1 — Total 399 299 63 37 Int J Gynecol Cancer 2008;18:453–459.

  25. Overall Recurrence and survivalin Borderline ovarian tumor N Recurred Died Stage I 686 29 9 Stage II & III 219 40 22 Total 905 69(7.6%) 31(3.4%) Rubin SC, Sutton GP (2001,Ovarian cancer 2nd edition)

  26. DNA Ploidy and Prognosis in Borderline Ovarian Tumor (I) Cancer 1992 69(10): 2510

  27. DNA Ploidy and Prognosis in Borderline Ovarian Tumor (II) Seidman JD et al.Cancer 1993;71:12 …DNA ploidy may be of little prognostic importance Harlow BL et al.Gynecol Oncol 1993;50:305 …Nocorrelation between DNA ploidy and Survival or Recurrence

  28. Mean Follow-up 36 months ( range 6-72 months ) No recurrence in 30 patients No death from disease Chemotherapy was given to 4 of 30 patients (1 stage IIC-Aneuploidy and 3 IIIC stage-Diploidy)

  29. CONCLUSION

  30. DNA was not recognized as an important prognostic factor in this study • More prolonged follow-up will be needed to evaluate the clinical correlation between DNA ploidy and recurrence / survival • Reassess the quality and quantity of tissue blocks for DNA Ploidy analysis

  31. REFERENCES

  32. ACKNOWLEDGEMENT

  33. M Steven Piver, MD David Marchetti, MD Judine Davis, MD Anthony Pivarunas, DO Pathology Department USLABS, CA

More Related